Included in the formulation
АТХ:G.03.G.A.08 Choriogonadotropin alfa
Pharmacodynamics:An analogue of human chorionic gonadotropin binds to the transmembrane receptors of luteinizing hormone located on the surfaces of teka cells and granulosa cells in the ovary. Initiation of oocyte meiosis, causes ovulation with the further formation of the yellow body and the subsequent support of its functions - the production of progesterone and estradiol.
Pharmacokinetics:After subcutaneous administration, the bioavailability is 40%.
The half-life is 30 hours.
Indications:It is used as an inducer of multiple ovulation during assisted reproductive technologies. Used to induce ovulation followed by luteinization in anovulatory infertility.
XIV.N80-N98.N97.0 Female infertility associated with the lack of ovulation
XIV.N80-N98.N97 Female infertility
XXI.Z30-Z39.Z31.1 Artificial insemination
Contraindications:Tumors of the pituitary and hypothalamus, ovarian neoplasms, breast or uterine cancer, thromboembolism,vaginal bleeding of unexplained etiology, defects of reproductive organs incompatible with pregnancy, presence of an ectopic pregnancy in the previous three months, primary ovarian failure, individual intolerance, childhood and advanced age.
Carefully:Systemic connective tissue diseases, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:For in vitro fertilization: subcutaneously, 250 mcg once, 1-2 days after the introduction of follicle-stimulating and luteinizing hormone with the preceding maturation of the follicle.
With anovulatory infertility: subcutaneously, 250 mcg once, 1-2 days after the last application of follicle-stimulating or luteinizing hormone. It is proposed to have sexual contact within 1 day after the administration of the drug.
The highest daily dose: 250 mcg.
The highest single dose: 250 mcg.
Side effects:Central and peripheral nervous system: a feeling of fatigue, headache, irritability, rarely - depression, anxiety.
Digestive system: gastralgia, nausea, vomiting, diarrhea.
Dermatological reactions: a transient rash.
Reproductive system: tenderness of mammary glands.
Local Reactions: pain, hyperemia at the injection site.
Allergic reactions.
Overdose:Syndrome of ovarian hyperstimulation with the formation of polycystosis, followed by rupture of cysts and development of ascites.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:Use of the drug is possible only in specialized centers for reproductive technologies.